Skip to main content
Top
Published in: BMC Cancer 1/2007

Open Access 01-12-2007 | Research article

Functional overload attenuates plantaris atrophy in tumor-bearing rats

Authors: Jeffrey S Otis, Simon J Lees, Jay H Williams

Published in: BMC Cancer | Issue 1/2007

Login to get access

Abstract

Background

Late stage cancer malignancies may result in severe skeletal muscle wasting, fatigue and reduced quality of life. Resistance training may attenuate these derangements in cancer patients, but how this hypertrophic response relates to normal muscle adaptations in healthy subjects is unknown. Here, we determined the effect of resistance training on muscle mass and myosin heavy chain (MHC) isoform composition in plantaris muscles from tumor-bearing (TB) rats.

Methods

Age- and gender-matched Buffalo rats were used for all studies (n = 6/group). Suspensions of Morris Hepatoma MH7777 cells or normal saline were injected subcutaneously into the dorsum. Six weeks after cell implantation, muscles from TB rats were harvested, weighed and processed for ATP-independent proteasome activity assays. Once tumor-induced atrophy had been established, subgroups of TB rats underwent unilateral, functional overload (FO). Healthy, sham-operated rats served as controls. After six weeks, the extent of plantaris hypertrophy was calculated and MHC isoform compositions were determined by gel electrophoresis.

Results

Six weeks of tumor growth reduced body mass and the relative masses of gastrocnemius, plantaris, tibialis anterior, extensor digitorum longus, and diaphragm muscles (p ≤ 0.05). Percent reductions in body mass had a strong, negative correlation to final tumor size (r = -0.78). ATP-independent proteasome activity was increased in plantaris muscles from TB rats (p ≤ 0.05). In healthy rats, functional overload (FO) increased plantaris mass ~44% compared to the contralateral control muscle, and increased the relative percentage of MHC type I and decreased the relative percentage of MHC type IIb compared to the sham-operated controls (p ≤ 0.05). Importantly, plantaris mass was increased ~24% in TB-FO rats and adaptations to MHC isoform composition were consistent with normal, resistance-trained muscles.

Conclusion

Despite significant skeletal muscle derangements due to cancer, muscle retains the capacity to respond normally to hypertrophic stimuli. Specifically, when challenged with functional overload, plantaris muscles from TB rats displayed greater relative mass, increased percentages of MHC type I and decreased percentages of MHC type IIb. Therefore, resistance training paradigms should provide relative morphological and functional benefits to cancer patients suffering from muscle wasting.
Appendix
Available only for authorised users
Literature
1.
go back to reference Saini A, Nasser AS, Stewart CE: Waste management – cytokines, growth factors and cachexia. Cytokine Growth Factor Rev. 2006, 17 (6): 475-486. 10.1016/j.cytogfr.2006.09.006.CrossRefPubMed Saini A, Nasser AS, Stewart CE: Waste management – cytokines, growth factors and cachexia. Cytokine Growth Factor Rev. 2006, 17 (6): 475-486. 10.1016/j.cytogfr.2006.09.006.CrossRefPubMed
2.
go back to reference Argiles JM, Alvarez B, Lopez-Soriano FJ: The metabolic basis of cancer cachexia. Med Res Rev. 1997, 17: 477-498. 10.1002/(SICI)1098-1128(199709)17:5<477::AID-MED3>3.0.CO;2-R.CrossRefPubMed Argiles JM, Alvarez B, Lopez-Soriano FJ: The metabolic basis of cancer cachexia. Med Res Rev. 1997, 17: 477-498. 10.1002/(SICI)1098-1128(199709)17:5<477::AID-MED3>3.0.CO;2-R.CrossRefPubMed
3.
go back to reference Barton BE: IL-6-like cytokines and cancer cachexia. Immuno Res. 2001, 23: 41-58. 10.1385/IR:23:1:41.CrossRef Barton BE: IL-6-like cytokines and cancer cachexia. Immuno Res. 2001, 23: 41-58. 10.1385/IR:23:1:41.CrossRef
4.
go back to reference Warren S: The immediate cause of death in cancer. Am J Med Sci. 1932, 184: 610-615. 10.1097/00000441-193211000-00002.CrossRef Warren S: The immediate cause of death in cancer. Am J Med Sci. 1932, 184: 610-615. 10.1097/00000441-193211000-00002.CrossRef
5.
go back to reference Argiles JM: Cancer-associated malnutrition. Eur J Oncol Nurs. 2005, 9: S39-S50. 10.1016/j.ejon.2005.09.006.CrossRefPubMed Argiles JM: Cancer-associated malnutrition. Eur J Oncol Nurs. 2005, 9: S39-S50. 10.1016/j.ejon.2005.09.006.CrossRefPubMed
6.
go back to reference Frost RA, Lang CH: Skeletal muscle cytokines: regulation by pathogen-associated molecules and catabolic hormones. Curr Opin Clin Nutr Metab Care. 2005, 8 (3): 255-263.CrossRefPubMed Frost RA, Lang CH: Skeletal muscle cytokines: regulation by pathogen-associated molecules and catabolic hormones. Curr Opin Clin Nutr Metab Care. 2005, 8 (3): 255-263.CrossRefPubMed
7.
go back to reference Lorite MJ, Smith HJ, Arnold JA, Morris A, Thompson MG, Tisdale MJ: Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF). Brit J Cancer. 2001, 85: 297-302. 10.1054/bjoc.2001.1879.CrossRefPubMedPubMedCentral Lorite MJ, Smith HJ, Arnold JA, Morris A, Thompson MG, Tisdale MJ: Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF). Brit J Cancer. 2001, 85: 297-302. 10.1054/bjoc.2001.1879.CrossRefPubMedPubMedCentral
8.
go back to reference Costelli P, Muscaritoli M, Bossola M, Penna F, Reffo P, Bonetto A, Busquets S, Bonelli G, Lopez-Soriano FJ, Doglietto GB, Argiles JM, Baccino FM, Fanelli FR: IGF-1 is downregulated in experimental cancer cachexia. Am J Physiol Regul Integr Comp Physiol. 2006, 291 (3): R674-R683.CrossRefPubMed Costelli P, Muscaritoli M, Bossola M, Penna F, Reffo P, Bonetto A, Busquets S, Bonelli G, Lopez-Soriano FJ, Doglietto GB, Argiles JM, Baccino FM, Fanelli FR: IGF-1 is downregulated in experimental cancer cachexia. Am J Physiol Regul Integr Comp Physiol. 2006, 291 (3): R674-R683.CrossRefPubMed
9.
go back to reference Temparis S, Asensi M, Attaix D: Increased ATP-ubiquitin-dependent proteolysis in skeletal muscles of tumor bearing rats. Cancer Res. 1994, 54: 5568-5573.PubMed Temparis S, Asensi M, Attaix D: Increased ATP-ubiquitin-dependent proteolysis in skeletal muscles of tumor bearing rats. Cancer Res. 1994, 54: 5568-5573.PubMed
10.
go back to reference Baracos VE, DeVito C, Hoyle DHR, Goldberg AL: Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. Am J Physiol. 1995, 268: E996-E1006.PubMed Baracos VE, DeVito C, Hoyle DHR, Goldberg AL: Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. Am J Physiol. 1995, 268: E996-E1006.PubMed
11.
go back to reference Costelli P, DeTullio R, Baccino FM, Melloni E: Activation of Ca2+-dependent proteolysis in skeletal and heart in cancer cachexia. Brit J Cancer. 2001, 84: 946-950. 10.1054/bjoc.2001.1696.CrossRefPubMedPubMedCentral Costelli P, DeTullio R, Baccino FM, Melloni E: Activation of Ca2+-dependent proteolysis in skeletal and heart in cancer cachexia. Brit J Cancer. 2001, 84: 946-950. 10.1054/bjoc.2001.1696.CrossRefPubMedPubMedCentral
12.
go back to reference Diffee GM, Kalfas K, Al-Majid S, McCarthy DO: Altered expression of skeletal muscle myosin isoforms in cancer cachexia. Am J Physiol Cell Physiol. 2002, 283: C1376-C1382.CrossRefPubMed Diffee GM, Kalfas K, Al-Majid S, McCarthy DO: Altered expression of skeletal muscle myosin isoforms in cancer cachexia. Am J Physiol Cell Physiol. 2002, 283: C1376-C1382.CrossRefPubMed
13.
go back to reference Otis JS, Roy RR, Edgerton VR, Talmadge RJ: Adaptations in metabolic capacity of rat soleus after paralysis. J Appl Physiol. 2004, 96 (2): 584-596. 10.1152/japplphysiol.00724.2003.CrossRefPubMed Otis JS, Roy RR, Edgerton VR, Talmadge RJ: Adaptations in metabolic capacity of rat soleus after paralysis. J Appl Physiol. 2004, 96 (2): 584-596. 10.1152/japplphysiol.00724.2003.CrossRefPubMed
14.
go back to reference Spangenburg EE, Talmadge RJ, Musch TI, Pfeifer PC, McAllister RM, Williams JH: Changes in skeletal muscle myosin heavy chain isoform content during congestive heart failure. Eur J Appl Physiol. 2002, 87: 182-186. 10.1007/s00421-002-0615-3.CrossRefPubMed Spangenburg EE, Talmadge RJ, Musch TI, Pfeifer PC, McAllister RM, Williams JH: Changes in skeletal muscle myosin heavy chain isoform content during congestive heart failure. Eur J Appl Physiol. 2002, 87: 182-186. 10.1007/s00421-002-0615-3.CrossRefPubMed
15.
go back to reference Talmadge RJ, Roy RR, Edgerton VR: Prominence of myosin heavy chain hybrid fibers in soleus muscle of spinal cord-transected rats. J Appl Physiol. 1995, 78: 1256-1265.PubMed Talmadge RJ, Roy RR, Edgerton VR: Prominence of myosin heavy chain hybrid fibers in soleus muscle of spinal cord-transected rats. J Appl Physiol. 1995, 78: 1256-1265.PubMed
16.
go back to reference Dunn SE, Michel RN: Coordinated expression of myosin heavy chain isoforms and metabolic enzymes within overloaded rat muscle fibers. Am J Physiol. 1997, 273 (2 Pt 1): C371-C383.PubMed Dunn SE, Michel RN: Coordinated expression of myosin heavy chain isoforms and metabolic enzymes within overloaded rat muscle fibers. Am J Physiol. 1997, 273 (2 Pt 1): C371-C383.PubMed
17.
go back to reference Evans WJ: Physical function in men and women with cancer. Effects of anemia and conditioning. Oncology. 2002, 16 (9 Suppl 10): 109-115.PubMed Evans WJ: Physical function in men and women with cancer. Effects of anemia and conditioning. Oncology. 2002, 16 (9 Suppl 10): 109-115.PubMed
18.
go back to reference Le Bricon T, Gugins S, Cynober L, Baracos VE: Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor-bearing rats. Metabolism. 1995, 44 (10): 1340-1348. 10.1016/0026-0495(95)90040-3.CrossRefPubMed Le Bricon T, Gugins S, Cynober L, Baracos VE: Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor-bearing rats. Metabolism. 1995, 44 (10): 1340-1348. 10.1016/0026-0495(95)90040-3.CrossRefPubMed
19.
go back to reference Driscoll J, Goldberg AL: Skeletal muscle proteasome can degrade proteins in an ATP-dependent process that does not require ubiquitin. Proc Natl Acad Sci USA. 1989, 86: 787-791. 10.1073/pnas.86.3.787.CrossRefPubMedPubMedCentral Driscoll J, Goldberg AL: Skeletal muscle proteasome can degrade proteins in an ATP-dependent process that does not require ubiquitin. Proc Natl Acad Sci USA. 1989, 86: 787-791. 10.1073/pnas.86.3.787.CrossRefPubMedPubMedCentral
20.
go back to reference Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976, 72: 248-254. 10.1016/0003-2697(76)90527-3.CrossRefPubMed Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976, 72: 248-254. 10.1016/0003-2697(76)90527-3.CrossRefPubMed
21.
go back to reference Spangenburg EE, Lees SJ, Otis JS, Musch TI, Talmadge RJ, Williams JH: Effects of moderate heart failure and functional overload on rat plantaris muscle. J Appl Physiol. 2002, 92: 18-24.PubMed Spangenburg EE, Lees SJ, Otis JS, Musch TI, Talmadge RJ, Williams JH: Effects of moderate heart failure and functional overload on rat plantaris muscle. J Appl Physiol. 2002, 92: 18-24.PubMed
22.
go back to reference Talmadge RJ, Roy RR: Electrophoretic separation of rat skeletal muscle myosin heavy-chain isoforms. J Appl Physiol. 1993, 75: 2337-2340.PubMed Talmadge RJ, Roy RR: Electrophoretic separation of rat skeletal muscle myosin heavy-chain isoforms. J Appl Physiol. 1993, 75: 2337-2340.PubMed
23.
go back to reference Tisdale MJ: The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting. J Support Oncol. 2005, 3 (3): 209-217.PubMed Tisdale MJ: The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting. J Support Oncol. 2005, 3 (3): 209-217.PubMed
24.
go back to reference Solomon V, Goldberg AL: Importance of the ATP-ubiquitin-proteasome pathway in the degradation of soluble and myofibrillar proteins in rabbit muscle extracts. J Biol Chem. 1996, 271 (43): 26690-26697. 10.1074/jbc.271.43.26690.CrossRefPubMed Solomon V, Goldberg AL: Importance of the ATP-ubiquitin-proteasome pathway in the degradation of soluble and myofibrillar proteins in rabbit muscle extracts. J Biol Chem. 1996, 271 (43): 26690-26697. 10.1074/jbc.271.43.26690.CrossRefPubMed
25.
go back to reference Lowe DA, Alway SE: Animal models for inducing muscle hypertrophy: are they relevant for clinical applications in humans?. J Orthop Sports Phys Ther. 2002, 32: 36-43.CrossRefPubMed Lowe DA, Alway SE: Animal models for inducing muscle hypertrophy: are they relevant for clinical applications in humans?. J Orthop Sports Phys Ther. 2002, 32: 36-43.CrossRefPubMed
26.
go back to reference al-Majid S, McCarthy DO: Resistance exercise training attenuates wasting of the extensor digitorum longus muscle in mice bearing the colon-26 adenocarcinoma. Biol Res Nurs. 2001, 2 (3): 155-166. 10.1177/109980040100200301.CrossRefPubMed al-Majid S, McCarthy DO: Resistance exercise training attenuates wasting of the extensor digitorum longus muscle in mice bearing the colon-26 adenocarcinoma. Biol Res Nurs. 2001, 2 (3): 155-166. 10.1177/109980040100200301.CrossRefPubMed
27.
go back to reference Roy RR, Baldwin KM, Edgerton VR: The plasticity of skeletal muscle: effects of neuromuscular activity. Exerc Sport Sci Rev. 1991, 19: 269-312. 10.1249/00003677-199101000-00008.CrossRefPubMed Roy RR, Baldwin KM, Edgerton VR: The plasticity of skeletal muscle: effects of neuromuscular activity. Exerc Sport Sci Rev. 1991, 19: 269-312. 10.1249/00003677-199101000-00008.CrossRefPubMed
28.
go back to reference Jiang B, Roy RR, Navarro C, Nguyen Q, Pierotti D, Edgerton VR: Enzymatic responses of cat medial gastrocnemius fiber to chronic inactivity. J Appl Physiol. 1991, 70 (1): 231-239.PubMed Jiang B, Roy RR, Navarro C, Nguyen Q, Pierotti D, Edgerton VR: Enzymatic responses of cat medial gastrocnemius fiber to chronic inactivity. J Appl Physiol. 1991, 70 (1): 231-239.PubMed
29.
go back to reference Pette D, Vrbova G: Neural control of phenotypic expression in mammalian muscle fibres. Muscle Nerve. 1985, 8: 676-689. 10.1002/mus.880080810.CrossRefPubMed Pette D, Vrbova G: Neural control of phenotypic expression in mammalian muscle fibres. Muscle Nerve. 1985, 8: 676-689. 10.1002/mus.880080810.CrossRefPubMed
30.
go back to reference Dalla Libera L, Sabbadini R, Renken C, Ravara B, Sandri M, Betto R, Angelini A, Vescovo G: Apoptosis in the skeletal muscle of rats with heart failure is associated with increased serum levels of TNF-alpha and sphingosine. J Mol Cell Cardiol. 2001, 33: 1871-1878. 10.1006/jmcc.2001.1453.CrossRefPubMed Dalla Libera L, Sabbadini R, Renken C, Ravara B, Sandri M, Betto R, Angelini A, Vescovo G: Apoptosis in the skeletal muscle of rats with heart failure is associated with increased serum levels of TNF-alpha and sphingosine. J Mol Cell Cardiol. 2001, 33: 1871-1878. 10.1006/jmcc.2001.1453.CrossRefPubMed
31.
go back to reference Moldawer LL, Copeland EM: Proinflammatory cytokines, nutritional support, and the cachexia syndrome: interactions and therapeutic options. Cancer. 1997, 79: 1828-1839. 10.1002/(SICI)1097-0142(19970501)79:9<1828::AID-CNCR28>3.0.CO;2-Z.CrossRefPubMed Moldawer LL, Copeland EM: Proinflammatory cytokines, nutritional support, and the cachexia syndrome: interactions and therapeutic options. Cancer. 1997, 79: 1828-1839. 10.1002/(SICI)1097-0142(19970501)79:9<1828::AID-CNCR28>3.0.CO;2-Z.CrossRefPubMed
32.
go back to reference Tisdale MJ: Loss of skeletal muscle in cancer: biochemical mechanisms. Front Biosci. 2001, 6: D164-D174. 10.2741/Tisdale.PubMed Tisdale MJ: Loss of skeletal muscle in cancer: biochemical mechanisms. Front Biosci. 2001, 6: D164-D174. 10.2741/Tisdale.PubMed
33.
go back to reference Murray S, Schell K, McCarthy DO, Albertini MR: Tumor growth, weight loss and cytokines in SCID mice. Cancer Lett. 1997, 111: 111-115. 10.1016/S0304-3835(96)04519-3.CrossRefPubMed Murray S, Schell K, McCarthy DO, Albertini MR: Tumor growth, weight loss and cytokines in SCID mice. Cancer Lett. 1997, 111: 111-115. 10.1016/S0304-3835(96)04519-3.CrossRefPubMed
34.
go back to reference Bottinelli R, Pellegrino MA, Canepari M, Rossi R, Reggiani C: Specific contributions of various muscle fibre types to human muscle performance: an in vitro study. J Electromyogr Kinesiol. 1999, 9 (2): 87-95. 10.1016/S1050-6411(98)00040-6.CrossRefPubMed Bottinelli R, Pellegrino MA, Canepari M, Rossi R, Reggiani C: Specific contributions of various muscle fibre types to human muscle performance: an in vitro study. J Electromyogr Kinesiol. 1999, 9 (2): 87-95. 10.1016/S1050-6411(98)00040-6.CrossRefPubMed
35.
go back to reference Vescovo G, Dalla Libera L, Serafini F, Leprotti C, Facchin L, Volterrani M, Ceconi C, Ambrosio GB: Improved exercise tolerance after losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition. Circulation. 1998, 98 (17): 1742-1749.CrossRefPubMed Vescovo G, Dalla Libera L, Serafini F, Leprotti C, Facchin L, Volterrani M, Ceconi C, Ambrosio GB: Improved exercise tolerance after losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition. Circulation. 1998, 98 (17): 1742-1749.CrossRefPubMed
36.
go back to reference Talmadge RJ: Myosin heavy chain isoform expression following reduced neuromuscular activity: potential regulatory mechanisms. Muscle Nerve. 2000, 23: 661-679. 10.1002/(SICI)1097-4598(200005)23:5<661::AID-MUS3>3.0.CO;2-J.CrossRefPubMed Talmadge RJ: Myosin heavy chain isoform expression following reduced neuromuscular activity: potential regulatory mechanisms. Muscle Nerve. 2000, 23: 661-679. 10.1002/(SICI)1097-4598(200005)23:5<661::AID-MUS3>3.0.CO;2-J.CrossRefPubMed
37.
go back to reference Lin J, Wu H, Tarr PT, Zhang CY, Wu Z, Boss O, Michael LF, Puigserver P, Isotani E, Olson EN, Lowell BB, Bassel-Duby R, Spiegelman BM: Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature. 2002, 418 (6899): 797-801. 10.1038/nature00904.CrossRefPubMed Lin J, Wu H, Tarr PT, Zhang CY, Wu Z, Boss O, Michael LF, Puigserver P, Isotani E, Olson EN, Lowell BB, Bassel-Duby R, Spiegelman BM: Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature. 2002, 418 (6899): 797-801. 10.1038/nature00904.CrossRefPubMed
38.
go back to reference Sandri M, Lin J, Handschin C, Yang W, Arany ZP, Lecker SH, Goldberg AL, Spiegelman BM: PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci USA. 2006, 103 (44): 16260-16265. 10.1073/pnas.0607795103.CrossRefPubMedPubMedCentral Sandri M, Lin J, Handschin C, Yang W, Arany ZP, Lecker SH, Goldberg AL, Spiegelman BM: PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci USA. 2006, 103 (44): 16260-16265. 10.1073/pnas.0607795103.CrossRefPubMedPubMedCentral
39.
go back to reference Baar K, Wende AR, Jones TE, Marison M, Nolte LA, Chen M, Kelly DP, Holloszy JO: Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC-1. FASEB J. 2002, 16 (14): 1879-1886. 10.1096/fj.02-0367com.CrossRefPubMed Baar K, Wende AR, Jones TE, Marison M, Nolte LA, Chen M, Kelly DP, Holloszy JO: Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC-1. FASEB J. 2002, 16 (14): 1879-1886. 10.1096/fj.02-0367com.CrossRefPubMed
Metadata
Title
Functional overload attenuates plantaris atrophy in tumor-bearing rats
Authors
Jeffrey S Otis
Simon J Lees
Jay H Williams
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2007
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-7-146

Other articles of this Issue 1/2007

BMC Cancer 1/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine